Clarivate

Clarivate is a British-American publicly traded analytics company (NYSE: CLVT) operating subscription-based data, software, and expert services across three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. It was formed in October 2016 from the $3.55 billion sale of Thomson Reuters' Intellectual Property and Science business to Onex Corporation and Baring Private Equity Asia.^[1][2][3].

The company is best known as home of the Web of Science citation database and the journal impact factor, alongside product families including ProQuest, Cortellis, Derwent, CompuMark, Darts-ip, and CPA Global. It reported revenue of $2.66 billion in 2022 with about 11,600 employees, and is led by CEO Matti Shem Tov since August 2024.^[1][2]

What It Does

Clarivate pairs enriched proprietary datasets with analytics, workflow software, and expert services. In Academia & Government it powers research discovery, bibliometrics, funding intelligence, and library systems; in Life Sciences & Healthcare it supports drug and device development, regulatory, commercialization, and medtech decisions; in Intellectual Property it provides patent search and analytics, trademark solutions, IP management software, annuities and renewals, and litigation intelligence.^[1]

Its data underpins widely used benchmarks: Clarivate calculates the impact factor of scientific journals through Journal Citation Reports based on Web of Science data, and publishes annual rankings such as Highly Cited Researchers, Citation Laureates, and Top 100 Global Innovators.^[2]

Products

Flagship products include the Web of Science platform and its Core Collection indexes, EndNote reference management, Journal Citation Reports, InCites benchmarking, ProQuest content collections and Ex Libris library platforms such as Alma, Cortellis life sciences intelligence suites covering clinical trials, competitive, deals, regulatory, and CMC intelligence plus BioWorld news, DRG market assessment and epidemiology datasets, Derwent patent search and the Derwent World Patents Index covering 44 patent authorities, CompuMark trademark screening and watch services, Darts-ip case law data, and IPfolio cloud IP management.^[1][2]

Recent additions include AI-oriented offerings such as Web of Science Research Assistant, the Nexus academic AI integration, IPOne for IP intelligence with trademark MCP servers, and APIs and XML data products across segments.^[1]

History

Thomson Reuters announced the $3.55 billion sale of its Intellectual Property and Science business on July 11, 2016; the transaction closed that October, creating independent Clarivate Analytics. In May 2019 the company merged with Churchill Capital Corp, a SPAC, to list on the New York Stock Exchange, later adopting ticker CLVT.^[2]

Acquisitions have shaped each segment: Publons (2017), Kopernio and TrademarkVision (2018), SequenceBase and Darts-ip (2019), Decision Resources Group and CPA Global (2020), and ProQuest in December 2021 in a deal valued at $5.3 billion. Leadership passed from Jerre Stead to Jonathan Gear in September 2022 and to former ProQuest CEO Matti Shem Tov in August 2024. Divestments include Techstreet (2020), MarkMonitor (2022), Valipat (2024), and ScholarOne, sold to Silverchair in November 2024.^[2]

Buyers and Use Cases

Customers span universities, funders, and libraries; pharmaceutical, biotech, and medtech companies; patent and trademark professionals at corporations and law firms; and investors using its innovation and drug pipeline benchmarks. Within alternative data, Clarivate's drug approval forecasts (Drugs to Watch) and patent analytics are consumed for healthcare and IP-related investment research, adjacent to providers like IQVIA and Evaluate in the Healthcare & Clinical category.^[1][2]